118 related articles for article (PubMed ID: 36446336)
1. Low Rate of Infectious Enterocolitis in Allogeneic Stem Cell Transplant Recipients with Acute Diarrhea: A Prospective Study by the GETH-TC.
Velao SR; Garcia Cadenas I; Cuesta MA; Sanchez-Ortega I; Fernández-Avilés F; Roldan E; Torrent A; Viguria MC; Villar S; Bento L; Yáñez L; Martino R; Piñana JL;
Acta Haematol; 2023; 146(2):161-165. PubMed ID: 36446336
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34
Scordo M; Shah GL; Kosuri S; Herrera DA; Cho C; Devlin SM; Maloy MA; Nieves J; Borrill T; Avecilla ST; Meagher RC; Carlow DC; O'Reilly RJ; Papadopoulos EB; Jakubowski AA; Koehne G; Gyurkocza B; Castro-Malaspina H; Tamari R; Perales MA; Giralt SA; Shaffer BC
Biol Blood Marrow Transplant; 2018 Jan; 24(1):133-141. PubMed ID: 28870777
[TBL] [Abstract][Full Text] [Related]
4. Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults.
Sung AD; Hassan S; Cardona DM; Wild D; Nichols KR; Mehdikhani H; Balmadrid B; Detweiler CJ; Shealy M; Cirrincione C; Li Z; Poleski M; Dalton TE; Siamakpour-Reihani S; Chao NJ; Sullivan KM
Biol Blood Marrow Transplant; 2018 Apr; 24(4):734-740. PubMed ID: 29246821
[TBL] [Abstract][Full Text] [Related]
5. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
6. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Connor MP; Loren AW; Hexner EO; Martin ME; Gill SI; Luger SM; Mangan JK; Perl AE; McCurdy SR; Pratz KW; Timlin C; Freyer CW; Carulli A; Catania C; Smith J; Hollander L; Zebrowski AM; Stadtmauer EA; Porter DL; Frey NV
Transplant Cell Ther; 2023 Feb; 29(2):113-118. PubMed ID: 36336258
[TBL] [Abstract][Full Text] [Related]
7. Colonization with Gastrointestinal Pathogens Prior to Hematopoietic Cell Transplantation and Associated Clinical Implications.
Kubiak J; Davidson E; Soave R; Kodiyanplakkal RP; Robertson A; Besien KV; Shore TB; Lee JR; Westblade LF; Satlin MJ
Transplant Cell Ther; 2021 Jun; 27(6):499.e1-499.e6. PubMed ID: 33811020
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic microangiopathy with concomitant GI aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome.
Zhang XH; Liu X; Wang QM; He Y; Zhu XL; Zhang JM; Han W; Chen H; Chen YH; Wang FR; Wang JZ; Zhang YY; Mo XD; Chen Y; Wang Y; Fu HX; Chang YJ; Xu LP; Liu KY; Huang XJ
Eur J Haematol; 2018 Feb; 100(2):171-181. PubMed ID: 29114931
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation.
Pasic I; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Mattsson J; Michelis FV
Ann Hematol; 2020 Jun; 99(6):1377-1387. PubMed ID: 32382774
[TBL] [Abstract][Full Text] [Related]
10. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
[TBL] [Abstract][Full Text] [Related]
11. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
[TBL] [Abstract][Full Text] [Related]
12. Clostridioides difficile Infection and Risk of Acute Graft-versus-Host Disease among Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Jabr R; El Atrouni W; Shune L; Telfah M; Gao G; He J; Abhyankar S; McGuirk J; Clough L
Transplant Cell Ther; 2021 Feb; 27(2):176.e1-176.e8. PubMed ID: 33830032
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation.
Salhotra A; Yang D; Mokhtari S; Hui S; Al Malki MM; Armenian S; Sigala B; Aldoss I; Pullarkat V; Forman S; Marcucci G; Nakamura R; Artz A; Wong J; Stein A
Leuk Lymphoma; 2022 May; 63(5):1220-1226. PubMed ID: 34879769
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
16. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
17. Diarrhea during the conditioning regimen is correlated with the occurrence of severe acute graft-versus-host disease through systemic release of inflammatory cytokines.
Liu D; Yan C; Xu L; Wang Y; Han W; Zhang X; Liu K; Huang X
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1567-75. PubMed ID: 20546909
[TBL] [Abstract][Full Text] [Related]
18. Recent decrease in non-relapse mortality due to GVHD and infection after allogeneic hematopoietic cell transplantation in non-remission acute leukemia.
Kurosawa S; Yakushijin K; Yamaguchi T; Atsuta Y; Nagamura-Inoue T; Akiyama H; Taniguchi S; Miyamura K; Takahashi S; Eto T; Ogawa H; Kurokawa M; Tanaka J; Kawa K; Kato K; Suzuki R; Morishima Y; Sakamaki H; Fukuda T
Bone Marrow Transplant; 2013 Sep; 48(9):1198-204. PubMed ID: 23562971
[TBL] [Abstract][Full Text] [Related]
19. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
20. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
